Rapastinel

Gate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update

Retrieved on: 
Thursday, September 29, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Molecule, Safety, Hospital, Institutional review board, Patient, Pharmacology, Investigational New Drug, IGF2R, Research, Northwestern University, Rockefeller University, Physical, NMDA, Division, Annual general meeting, Sleep, The International Journal of Neuropsychopharmacology, Northwestern, Hippocampus, Depression, MADRS, FDA, Literature, Lists of diseases, IND, GABA, Mental health, CEO, Board of directors, Method, Board, Eli Lilly, Electroencephalography, Plasma, Half-life, Precision medicine, Canadian International Council, Psychiatry, Biomarker, Publication, Massachusetts General Hospital, Therapy, Interneuron, Ataxia, Prefrontal cortex, Authorization, CNS, EEG, AbbVie, NMDAR, Depressive, Pharmaceutical industry, Apimostinel, MDD, Rapastinel

Publication highlights robust preclinical profile and novel mechanism for lead Phase 2 clinical program, Zelquistinel

Key Points: 
  • Publication highlights robust preclinical profile and novel mechanism for lead Phase 2 clinical program, Zelquistinel
    The peer-reviewed manuscript spotlights Zelquistinels novel mechanism and pharmacology by which it elicits rapid and long-lasting antidepressant effects.
  • These data highlight Zelquistinels novel, potent, and highly differentiated mechanism of action with potential for a significantly improved safety profile compared to other NMDAR-targeted antidepressants in development for depressive disorders.
  • Published in several peer-reviewed journals highlighting novel NMDAR mechanism and antidepressant activity of lead programs.
  • Gate Neurosciences lead programs are highly differentiated from other NMDAR-targeted antidepressants by acting through positive modulation instead of antagonism.

Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases

Retrieved on: 
Tuesday, August 23, 2022
Biotechnology, Pharmaceutical, Health, Mental Health, AbbVie, University, Wilfrid Sellars, Central nervous system disease, Central nervous system, Precision medicine, Outline of health sciences, Lists of diseases, Senior, Dean, Ketamine, Therapy, Allergan, Mental health, Biomarker, MDD, NMDAR, Acquisition, Drug development, CNS, NMDA, Patient, Pharmaceutical industry, Gate, Apimostinel, Rapastinel

Gate Neurosciences today announced it has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.

Key Points: 
  • Gate Neurosciences today announced it has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.
  • The company is focused on developing novel mechanisms that address synaptic dysfunction underlying neuropsychiatric and cognitive disorders, including major depressive disorder (MDD).
  • Gate will provide a strategic business update in the coming weeks that will provide additional information on its diverse development portfolio and major recent and upcoming milestones.
  • The company is developing a portfolio of novel mechanisms of action that enhance synaptic function to address neuropsychiatric and neurocognitive diseases, including major depressive disorder (MDD).

Appaloosa Issues Statement Regarding Allergan’s Failed Anti-Depression Study

Retrieved on: 
Thursday, March 7, 2019
Health, Pharmaceutical, Other Health, Professional services, Finance, Antidepressants, Peptides, Horses, Nootropics, Rapastinel, Drugs, Appaloosa, Allergan, Branches of biology

Appaloosa LP today issued a statement in response to Allergan plcs (NYSE: AGN) (Allergan) March 6, 2019 announcement that its drug, Rapastinel, failed a late stage study for treatment of major depressive disorder:

Key Points: 
  • Appaloosa LP today issued a statement in response to Allergan plcs (NYSE: AGN) (Allergan) March 6, 2019 announcement that its drug, Rapastinel, failed a late stage study for treatment of major depressive disorder:
    Yesterdays announcement that Allergans marquee pipeline drug, Rapastinel, had spectacularly failed its Phase III trials should make apparent to all that the Companys Open Science business model is broken.
  • The Boards misplaced fear of "disrupting" Allergan is wearing thin as an excuse for inaction and can only perpetuate further erosion in the shareholders investment.
  • Funds advised by Appaloosa LP (Appaloosa) have submitted to Allergan plc (Allergan) a shareholder proposal to separate the roles of Chairman and Chief Executive Officer to be considered at Allergans 2019 annual general meeting of shareholders.
  • This communication is not a solicitation of proxies and Appaloosa is not seeking authority to vote any proxy in connection with Allergans annual general meeting.

Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)

Retrieved on: 
Monday, July 23, 2018
Antidepressants, Medical research, Health, Neurochemistry, AGN-241751, Rapastinel, Fast track, Allergan, Food and Drug Administration

DUBLIN, July 23, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has granted Fast Track designation for AGN-241751, an investigational new treatment for Major Depressive Disorder (MDD).

Key Points: 
  • DUBLIN, July 23, 2018 /PRNewswire/ --Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has granted Fast Track designation for AGN-241751, an investigational new treatment for Major Depressive Disorder (MDD).
  • The Fast Track designation will allow Allergan to work more closely with the FDA to bring AGN-241751 to patients as soon as possible."
  • Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
  • Allergan acquired AGN-241751 as part of its ongoing research effort with Aptinyx, Inc.
    AGN-241751 development follows Rapastinel, which received FDA Fast Track Designation in 2014 and Breakthrough Designation from the FDA in 2016.